HeFH in real life,how to: More evolocumab than authorized

Abstract

Get full access to this article

View all access options for this article.

References

Sabatine

Giugliano

Keech

, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–1722.

Pećin

Hartgers

Hovingh

, et al. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. Eur J Prev Cardiol 2017; 24: 1383–1401.

U.S. National Library of Medicine. ClinicalTrial.gov. https://clinicaltrials.gov/ct2/show/NCT01624142 (2012, accessed 2 August 2018).

Amgen Inc. One Amgen Center Drive Thousand Oaks, California. https://pi.amgen.com//media/amgen/repositorysites/piamgen-com/repatha/repatha_pi_hcp_english.pdf (2019, accessed 2 August 2018).

Sinning

Landmesser

. Effective low-density lipoprotein-lowering therapy: Implementation in clinical practice. Eur J Prev Cardiol 2017; 24: 71–76.

Ellis

Pang

Schultz

, et al. New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials. Eur J Prev Cardiol 2017; 24: 1200–1205.

Raal

Hovingh

Blom

, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: An interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol 2017; 5: 280–290.